TY - JOUR
T1 - A Gastroenterologist's Guide to Probiotics
AU - Ciorba, Matthew A.
N1 - Funding Information:
Funding This work is partially supported by NIH grant DK089016 .
PY - 2012/9
Y1 - 2012/9
N2 - The enteric microbiota contribute to gastrointestinal health, and their disruption has been associated with many disease states. Some patients consume probiotic products in attempts to manipulate the intestinal microbiota for health benefit. It is important for gastroenterologists to improve their understanding of the mechanisms of probiotics and the evidence that support their use in practice. Clinical trials have assessed the therapeutic effects of probiotic agents for several disorders, including antibiotic- or Clostridium difficile-associated diarrhea, irritable bowel syndrome, and the inflammatory bowel diseases. Although probiotic research is a rapidly evolving field, there are sufficient data to justify a trial of probiotics for treatment or prevention of some of these conditions. However, the capacity of probiotics to modify disease symptoms is likely to be modest and varies among probiotic strains-not all probiotics are right for all diseases. The current review provides condition-specific rationale for using probiotic therapy and literature-based recommendations.
AB - The enteric microbiota contribute to gastrointestinal health, and their disruption has been associated with many disease states. Some patients consume probiotic products in attempts to manipulate the intestinal microbiota for health benefit. It is important for gastroenterologists to improve their understanding of the mechanisms of probiotics and the evidence that support their use in practice. Clinical trials have assessed the therapeutic effects of probiotic agents for several disorders, including antibiotic- or Clostridium difficile-associated diarrhea, irritable bowel syndrome, and the inflammatory bowel diseases. Although probiotic research is a rapidly evolving field, there are sufficient data to justify a trial of probiotics for treatment or prevention of some of these conditions. However, the capacity of probiotics to modify disease symptoms is likely to be modest and varies among probiotic strains-not all probiotics are right for all diseases. The current review provides condition-specific rationale for using probiotic therapy and literature-based recommendations.
KW - Clostridium difficile
KW - Crohn's Disease and Colitis
KW - IBD
KW - IBS
KW - Pouchitis
KW - Yogurt
UR - http://www.scopus.com/inward/record.url?scp=84865314484&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2012.03.024
DO - 10.1016/j.cgh.2012.03.024
M3 - Review article
C2 - 22504002
AN - SCOPUS:84865314484
SN - 1542-3565
VL - 10
SP - 960
EP - 968
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 9
ER -